Lercanidipine ameliorated doxorubicin-induced neuroinflammation and maintained the expressions of choline acetyltransferase via enhancing the levels of PI3K/AKT/HIF1-α expressions.
Apoptosis
Brain
HIF1-α
Inflammation
Learning and memory
Lercanidipine
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
13 Feb 2024
13 Feb 2024
Historique:
received:
08
08
2023
accepted:
07
11
2023
medline:
13
2
2024
pubmed:
13
2
2024
entrez:
13
2
2024
Statut:
epublish
Résumé
Doxorubicin (DOX) may cause various neurological side effects in the brain. Lercanidipine (LRD) has antioxidant, anti-inflammatory, and anti-apoptotic properties. The aim of this study was to investigate the potential benefits of. Lercanidipine in reducing doxorubicin-induced neuroinflammation and maintaining the expressions of choline acetyltransferase. Thirty-two adult Wistar albino female rats were divided into four groups as Control, DOX (20 mg/kg intraperitoneally), DOX + LRD 0.5 (0.5 mg/kg orally), and DOX + LRD2(2 mg/kg orally). Twenty-four hours after the last drug administration (9th day), brain tissues were taken for histopathological, immunohistochemical (choline acetyltransferase [CHAT], interleukin-10 [IL-10], and caspase-3 [Cas-3] staining), biochemical (total antioxidant status [TAS], total oxidant status [TOS], and oxidative stress index [OSI]), and genetic analyzes (PI3K/AKT/HIF1-α and IL-6 gene expressions). Histopathological analyses revealed hyperemia, slight hemorrhage, degeneration, neuronal loss, gliosis in the cerebellum, and neuronal loss in the brain cortex and hippocampus in the DOX group. According to other analyzes, decreased CHAT, PI3K, AKT, HIF1-α and increased IL-6, IL-10, Cas-3 expression were observed in the DOX group. Both LRD doses reversed all these findings, but LRD2 was observed to be more effective. In conclusion, we determined that LRD has potential therapeutic effect by reducing DOX-induced neuroinflammation, oxidative stress and apoptosis in brain tissues.
Sections du résumé
BACKGROUND
BACKGROUND
Doxorubicin (DOX) may cause various neurological side effects in the brain. Lercanidipine (LRD) has antioxidant, anti-inflammatory, and anti-apoptotic properties. The aim of this study was to investigate the potential benefits of.
METHODS AND RESULTS
RESULTS
Lercanidipine in reducing doxorubicin-induced neuroinflammation and maintaining the expressions of choline acetyltransferase. Thirty-two adult Wistar albino female rats were divided into four groups as Control, DOX (20 mg/kg intraperitoneally), DOX + LRD 0.5 (0.5 mg/kg orally), and DOX + LRD2(2 mg/kg orally). Twenty-four hours after the last drug administration (9th day), brain tissues were taken for histopathological, immunohistochemical (choline acetyltransferase [CHAT], interleukin-10 [IL-10], and caspase-3 [Cas-3] staining), biochemical (total antioxidant status [TAS], total oxidant status [TOS], and oxidative stress index [OSI]), and genetic analyzes (PI3K/AKT/HIF1-α and IL-6 gene expressions). Histopathological analyses revealed hyperemia, slight hemorrhage, degeneration, neuronal loss, gliosis in the cerebellum, and neuronal loss in the brain cortex and hippocampus in the DOX group. According to other analyzes, decreased CHAT, PI3K, AKT, HIF1-α and increased IL-6, IL-10, Cas-3 expression were observed in the DOX group.
CONCLUSIONS
CONCLUSIONS
Both LRD doses reversed all these findings, but LRD2 was observed to be more effective. In conclusion, we determined that LRD has potential therapeutic effect by reducing DOX-induced neuroinflammation, oxidative stress and apoptosis in brain tissues.
Identifiants
pubmed: 38349603
doi: 10.1007/s11033-023-09024-w
pii: 10.1007/s11033-023-09024-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
300Subventions
Organisme : Suleyman Demirel University Scientific Research Projects Coordination Unit
ID : TSG-2022-8783
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Nature B.V.
Références
Kalyanaraman B (2020) Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree? Redox Biol 29:101394. https://doi.org/10.1016/j.redox.2019.101394
doi: 10.1016/j.redox.2019.101394
pubmed: 31790851
Alsaud MM, Alhowail AH, Aldubayan MA, Almami IS (2023) The ameliorative effect of pioglitazone against neuroinflammation caused by doxorubicin in rats. Molecules 28(12):4775. https://doi.org/10.3390/molecules28124775
doi: 10.3390/molecules28124775
pubmed: 37375330
pmcid: 10304172
Hu C, Zhang X, Zhang N, Wei W, Li L, Ma Z, Tang Q (2020) Osteocrin attenuates inflammation, oxidative stress, apoptosis, and cardiac dysfunction in doxorubicin-induced cardiotoxicity. Clin Transl Med. https://doi.org/10.1002/ctm2.124
doi: 10.1002/ctm2.124
pubmed: 33377659
pmcid: 7744027
Du J, Zhang A, Li J, Liu X, Wu S, Wang B et al (2021) Doxorubicin-Induced cognitive impairment: the mechanistic insights. Front Oncol. https://doi.org/10.3389/fonc.2021.673340
doi: 10.3389/fonc.2021.673340
pubmed: 35155211
pmcid: 8756138
Ongnok B, Chattipakorn N, Chattipakorn SC (2020) Doxorubicin and cisplatin induced cognitive impairment: the possible mechanisms and interventions. Exp Neurol 324:113118. https://doi.org/10.1016/j.expneurol.2019.113118
doi: 10.1016/j.expneurol.2019.113118
pubmed: 31756316
Syukri A, Budu Hatta M, Amir M, Rohman MS, Mappangara I et al (2022) Doxorubicin induced immune abnormalities and inflammatory responses via HMGB1, HIF1-α and VEGF pathway in progressive of cardiovascular damage. Ann Med Surg. https://doi.org/10.1016/j.amsu.2022.103501
doi: 10.1016/j.amsu.2022.103501
Lawrence WT, Norton JA, Harvey AK, Gorschboth CM, Talbot TL (1986) Grotendorst GR (1986) doxorubicin-induced impairment of wound healing in rats. J Natl Cancer Inst 76(1):119–126
pubmed: 3455735
Barrientos R, Kitt M, Watkins L, Maier S (2015) Neuroinflammation in the normal aging hippocampus. Neuroscience 309:84–99. https://doi.org/10.1016/j.neuroscience.2015.03.007
doi: 10.1016/j.neuroscience.2015.03.007
pubmed: 25772789
Liu J, Gao S, Wei L, Xiong W, Lu Y, Song X et al (2022) Choline acetyltransferase and vesicular acetylcholine transporter are required for metamorphosis, reproduction, and insecticide susceptibility in Tribolium castaneum. Gene 842:146794. https://doi.org/10.1016/j.gene.2022.146794
doi: 10.1016/j.gene.2022.146794
pubmed: 35952841
Kyung J, Kim D, Shin K, Park D, Hong SC, Kim TM et al (2023) Repeated Intravenous Administration of Human neural stem cells encoding Choline Acetyltransferase Gene exhibits anti-ageing activities displaying enhanced cognitive and physical functions. Doi: 10.20944/preprints202307.0748.v1
Masoud M, Ahmed S (2022) Terminalia muelleri extract supplementation alleviates doxorubicin-induced neurotoxicity in rats: involvement of oxidative stress and neuroinflammation, apoptosis, extracellular signal-regulated kinase, and mammalian target of rapamycin. Egypt Pharm J. https://doi.org/10.4103/epj.epj_56_21
doi: 10.4103/epj.epj_56_21
Bachmeier C, Beaulieu-Abdelahad D, Mullan M, Paris D (2011) Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood–brain barrier. Eur J Pharmacol 659(2–3):124–129. https://doi.org/10.1016/j.ejphar.2011.03.048
doi: 10.1016/j.ejphar.2011.03.048
pubmed: 21497592
Vasigar P, Batmanabane M (2013) Anti-inflammatory activity of calcium channel blocker lercanidipine hydrochloride. J Pharmacol Pharmacother 4(4):238–242. https://doi.org/10.4103/0976-500x.119707
doi: 10.4103/0976-500x.119707
pubmed: 24250199
pmcid: 3825998
Farah R, Shurtz-Swirski R, Khamisy-Farah R (2012) Lercanidipine effect on polymorphonuclear leukocyte-related inflammation and insulin resistance in essential hypertension patients. Cardiol Ther. https://doi.org/10.1007/s40119-012-0004-x
doi: 10.1007/s40119-012-0004-x
pubmed: 25135158
pmcid: 4107444
Tomlinson B, Benzie IF (2003) Antioxidant effect of lercanidipine. Hypertension 42(4):e10–e11. https://doi.org/10.1161/01.HYP.0000091372.14174.89
doi: 10.1161/01.HYP.0000091372.14174.89
pubmed: 12953020
Panneerpandian P, Rao DB, Ganesan K (2021) Calcium channel blockers lercanidipine and amlodipine inhibit YY1/ERK/TGF-β mediated transcription and sensitize the gastric cancer cells to doxorubicin. Toxicol In Vitro. 74:105–152. https://doi.org/10.1016/j.tiv.2021.105152
doi: 10.1016/j.tiv.2021.105152
Jasim ST, Al-Kuraishy HM, Al-Gareeb AI (2019) Gingko Biloba protects cardiomyocytes against acute doxorubicin induced cardiotoxicity by suppressing oxidative stress. J Pak Med Assoc 69:S103–S107
Gupta S, Sharma U, Jagannathan NR, Gupta YK (2017) Neuroprotective effect of lercanidipine in middle cerebral artery occlusion model of Stroke in rats. Exp Neurol 288:25–37. https://doi.org/10.1016/j.expneurol.2016.10.014
doi: 10.1016/j.expneurol.2016.10.014
pubmed: 27794423
Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37(4):277–285. https://doi.org/10.1016/j.clinbiochem.2003.11.015
doi: 10.1016/j.clinbiochem.2003.11.015
pubmed: 15003729
Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38(12):1103–1111. https://doi.org/10.1016/j.clinbiochem.2005.08.008
doi: 10.1016/j.clinbiochem.2005.08.008
pubmed: 16214125
Carvalho C, Santos R, Cardoso S, Correia S, Oliveira P, Santos M, Moreira P (2009) Doxorubicin: the Good, the bad and the Ugly Effect. Curr Med Chem 16(25):3267–3285. https://doi.org/10.2174/092986709788803312
doi: 10.2174/092986709788803312
pubmed: 19548866
Christidi E, Brunham LR (2021) Regulated cell death pathways in doxorubicin-induced cardiotoxicity. Cell Death Dis 12(4):339. https://doi.org/10.1038/s41419-021-03614-x
doi: 10.1038/s41419-021-03614-x
pubmed: 33795647
pmcid: 8017015
Galea I (2021) The blood–brain barrier in Systemic infection and inflammation. Cell Mol Immunol 18(11):2489–2501. https://doi.org/10.1038/s41423-021-00757-x
doi: 10.1038/s41423-021-00757-x
pubmed: 34594000
pmcid: 8481764
Ramani T, Auletta CS, Weinstock D, Mounho-Zamora B, Ryan PC, Salcedo TW (2015) Cytokines. Int J Toxicol 34(4):355–365. https://doi.org/10.1177/1091581815584918
doi: 10.1177/1091581815584918
pubmed: 26015504
Mangalmurti A, Lukens JR (2022) How neurons die in Alzheimer’s disease: implications for neuroinflammation. Curr Opin Neurobiol 75:102–575. https://doi.org/10.1016/j.conb.2022.102575
doi: 10.1016/j.conb.2022.102575
Murley AG, Rowe JB (2018) Neurotransmitter deficits from frontotemporal lobar degeneration. Brain 141(5):1263–1285. https://doi.org/10.1093/brain/awx327
doi: 10.1093/brain/awx327
pubmed: 29373632
pmcid: 5917782
Haam J, Yakel JL (2017) Cholinergic modulation of the hippocampal region and memory function. J Neurochem 142:111–121. https://doi.org/10.1111/jnc.14052
doi: 10.1111/jnc.14052
pubmed: 28791706
pmcid: 5645066
Chen MH, Hong CL, Wang YT, Wang TJ, Chen JR (2022) The effect of astaxanthin treatment on the rat model of fetal alcohol spectrum disorders (FASD). Brain Res Bull 183:57–72. https://doi.org/10.1016/j.brainresbull.2022.02.017
doi: 10.1016/j.brainresbull.2022.02.017
pubmed: 35227769
Yin X, Wang Y, Li J, Guo ZV (2022) Lateralization of short-term memory in the frontal cortex. Cell Rep 40(7):111190. https://doi.org/10.1016/j.celrep.2022.111190
doi: 10.1016/j.celrep.2022.111190
pubmed: 35977520
Jang DC, Kim SJ (2019) Plasticity leading to cerebellum-dependent learning: two different regions, two different types. Pflügers Arch Eur J Physiol 471(7):927–934. https://doi.org/10.1007/s00424-019-02282-3
doi: 10.1007/s00424-019-02282-3
Usta Sofu G, Erzurumlu Y, Karaca U, Candan IA, Savran M, Asci H, Hasseyid N (2022) Melatonin receptor agonist ramelteon alleviates experimental acute ocular inflammation via HIF-1Α/VEGF/E-NOS signaling. Eur J Ophthalmol 33(2):1018–1025. https://doi.org/10.1177/11206721221123878
doi: 10.1177/11206721221123878
Xu Q, Briggs J, Park S, Niu G, Kortylewski M, Zhang S et al (2005) Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24(36):5552–5560. https://doi.org/10.1038/sj.onc.1208719
doi: 10.1038/sj.onc.1208719
pubmed: 16007214